Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $26.43

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $26.4286.

A number of research analysts have weighed in on KALV shares. JMP Securities raised their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research note on Friday, September 12th. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th.

KalVista Pharmaceuticals Stock Down 0.9%

NASDAQ KALV opened at $10.89 on Friday. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $17.28. The business has a 50 day moving average price of $12.44 and a 200-day moving average price of $12.84. The company has a market cap of $550.20 million, a price-to-earnings ratio of -2.76 and a beta of -0.04.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.97 million. On average, equities research analysts anticipate that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 10,940 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $144,626.80. Following the transaction, the chief executive officer owned 386,858 shares of the company’s stock, valued at $5,114,262.76. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,942 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $38,893.24. Following the completion of the sale, the insider directly owned 119,841 shares of the company’s stock, valued at $1,584,298.02. The trade was a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 26,856 shares of company stock worth $374,910 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in KalVista Pharmaceuticals by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock worth $26,526,000 after purchasing an additional 43,355 shares during the last quarter. Woodline Partners LP boosted its stake in shares of KalVista Pharmaceuticals by 25.5% in the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock worth $18,666,000 after buying an additional 329,068 shares during the last quarter. Emerald Advisers LLC boosted its stake in shares of KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after buying an additional 313,205 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after acquiring an additional 905,053 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of KalVista Pharmaceuticals by 2.8% during the second quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company’s stock valued at $10,642,000 after acquiring an additional 25,971 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).